vs
EXACT SCIENCES CORP（EXAS）与Veralto（VLTO）财务数据对比。点击上方公司名可切换其他公司
Veralto的季度营收约是EXACT SCIENCES CORP的1.6倍（$1.4B vs $878.4M），Veralto净利率更高（17.9% vs -9.8%，领先27.6%），EXACT SCIENCES CORP同比增速更快（23.1% vs 6.8%），Veralto自由现金流更多（$170.0M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 6.8%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Veralto是总部位于美国马萨诸塞州沃尔瑟姆的科技企业，核心业务覆盖水分析、水处理、标识喷码、包装及色彩管理相关产品的研发与生产，面向全球多领域客户提供适配的技术产品及配套服务。
EXAS vs VLTO — 直观对比
营收规模更大
VLTO
是对方的1.6倍
$878.4M
营收增速更快
EXAS
高出16.4%
6.8%
净利率更高
VLTO
高出27.6%
-9.8%
自由现金流更多
VLTO
多$49.6M
$120.4M
两年增速更快
EXAS
近两年复合增速
6.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.4B |
| 净利润 | $-86.0M | $254.0M |
| 毛利率 | 70.1% | 60.1% |
| 营业利润率 | -9.4% | 23.8% |
| 净利率 | -9.8% | 17.9% |
| 营收同比 | 23.1% | 6.8% |
| 净利润同比 | 90.1% | 12.9% |
| 每股收益（稀释后） | $-0.45 | $1.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASVLTO
| Q1 26 | — | $1.4B | ||
| Q4 25 | $878.4M | $1.4B | ||
| Q3 25 | $850.7M | $1.4B | ||
| Q2 25 | $811.1M | $1.3B | ||
| Q1 25 | $706.8M | — | ||
| Q4 24 | $713.4M | $1.3B | ||
| Q3 24 | $708.7M | $1.3B | ||
| Q2 24 | $699.3M | $1.3B |
净利润EXASVLTO
| Q1 26 | — | $254.0M | ||
| Q4 25 | $-86.0M | $239.0M | ||
| Q3 25 | $-19.6M | $222.0M | ||
| Q2 25 | $-1.2M | $225.0M | ||
| Q1 25 | $-101.2M | — | ||
| Q4 24 | $-864.6M | $227.0M | ||
| Q3 24 | $-38.2M | $219.0M | ||
| Q2 24 | $-15.8M | $203.0M |
毛利率EXASVLTO
| Q1 26 | — | 60.1% | ||
| Q4 25 | 70.1% | 60.1% | ||
| Q3 25 | 68.6% | 60.0% | ||
| Q2 25 | 69.3% | 60.4% | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | 59.6% | ||
| Q3 24 | 69.4% | 59.6% | ||
| Q2 24 | 69.8% | 60.1% |
营业利润率EXASVLTO
| Q1 26 | — | 23.8% | ||
| Q4 25 | -9.4% | 23.2% | ||
| Q3 25 | -3.0% | 22.8% | ||
| Q2 25 | -0.3% | 24.2% | ||
| Q1 25 | -13.6% | — | ||
| Q4 24 | -122.8% | 22.9% | ||
| Q3 24 | -5.6% | 23.4% | ||
| Q2 24 | -3.8% | 23.2% |
净利率EXASVLTO
| Q1 26 | — | 17.9% | ||
| Q4 25 | -9.8% | 17.0% | ||
| Q3 25 | -2.3% | 16.2% | ||
| Q2 25 | -0.1% | 16.9% | ||
| Q1 25 | -14.3% | — | ||
| Q4 24 | -121.2% | 16.9% | ||
| Q3 24 | -5.4% | 16.7% | ||
| Q2 24 | -2.3% | 15.8% |
每股收益（稀释后）EXASVLTO
| Q1 26 | — | $1.02 | ||
| Q4 25 | $-0.45 | $0.95 | ||
| Q3 25 | $-0.10 | $0.89 | ||
| Q2 25 | $-0.01 | $0.90 | ||
| Q1 25 | $-0.54 | — | ||
| Q4 24 | $-4.69 | $0.91 | ||
| Q3 24 | $-0.21 | $0.88 | ||
| Q2 24 | $-0.09 | $0.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | — |
| 总资产 | $5.9B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASVLTO
| Q1 26 | — | — | ||
| Q4 25 | $964.7M | $1.8B | ||
| Q3 25 | $1.0B | $1.6B | ||
| Q2 25 | $858.4M | $1.2B | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | $1.1B | ||
| Q3 24 | $1.0B | $1.3B | ||
| Q2 24 | $946.8M | $1.0B |
总债务EXASVLTO
| Q1 26 | — | — | ||
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.6B | ||
| Q2 24 | — | $2.6B |
股东权益EXASVLTO
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $2.8B | ||
| Q3 25 | $2.5B | $2.7B | ||
| Q2 25 | $2.5B | $2.3B | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | $2.0B | ||
| Q3 24 | $3.2B | $2.0B | ||
| Q2 24 | $3.2B | $1.7B |
总资产EXASVLTO
| Q1 26 | — | — | ||
| Q4 25 | $5.9B | $7.4B | ||
| Q3 25 | $5.9B | $7.2B | ||
| Q2 25 | $5.8B | $6.6B | ||
| Q1 25 | $5.7B | — | ||
| Q4 24 | $5.9B | $6.4B | ||
| Q3 24 | $6.7B | $6.3B | ||
| Q2 24 | $6.7B | $5.9B |
负债/权益比EXASVLTO
| Q1 26 | — | — | ||
| Q4 25 | — | 0.94× | ||
| Q3 25 | — | 1.01× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.28× | ||
| Q3 24 | — | 1.35× | ||
| Q2 24 | — | 1.57× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $170.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 12.0% |
| 资本支出强度资本支出/营收 | 3.6% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 0.72× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $893.0M |
8季度趋势，按日历期对齐
经营现金流EXASVLTO
| Q1 26 | — | $182.0M | ||
| Q4 25 | $151.7M | $270.0M | ||
| Q3 25 | $219.9M | $339.0M | ||
| Q2 25 | $89.0M | $157.0M | ||
| Q1 25 | $30.8M | — | ||
| Q4 24 | $47.1M | $285.0M | ||
| Q3 24 | $138.7M | $224.0M | ||
| Q2 24 | $107.1M | $251.0M |
自由现金流EXASVLTO
| Q1 26 | — | $170.0M | ||
| Q4 25 | $120.4M | $258.0M | ||
| Q3 25 | $190.0M | $323.0M | ||
| Q2 25 | $46.7M | $142.0M | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | $263.0M | ||
| Q3 24 | $112.6M | $215.0M | ||
| Q2 24 | $71.2M | $240.0M |
自由现金流率EXASVLTO
| Q1 26 | — | 12.0% | ||
| Q4 25 | 13.7% | 18.4% | ||
| Q3 25 | 22.3% | 23.6% | ||
| Q2 25 | 5.8% | 10.7% | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | 19.6% | ||
| Q3 24 | 15.9% | 16.4% | ||
| Q2 24 | 10.2% | 18.6% |
资本支出强度EXASVLTO
| Q1 26 | — | 0.8% | ||
| Q4 25 | 3.6% | 0.9% | ||
| Q3 25 | 3.5% | 1.2% | ||
| Q2 25 | 5.2% | 1.1% | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | 1.6% | ||
| Q3 24 | 3.7% | 0.7% | ||
| Q2 24 | 5.1% | 0.9% |
现金转化率EXASVLTO
| Q1 26 | — | 0.72× | ||
| Q4 25 | — | 1.13× | ||
| Q3 25 | — | 1.53× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.26× | ||
| Q3 24 | — | 1.02× | ||
| Q2 24 | — | 1.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
VLTO
暂无分部数据
